Upregulated expression of pyruvate kinase M2 mRNA predicts poor prognosis in lung adenocarcinoma

PeerJ

article

Guiping Wang¹  Yingying Zhong²  Jiecong Liang³  Zhibin Li¹  Yun Ye² 

[1] Department of Pharmacy, Guangzhou Health Science College;College of Biological and Chemical Engineering, Guangxi University of Science and Technology;Department of General Surgery, Guangzhou Women and Children Medical Center

关键词: Lung adenocarcinoma (LUAD);    Prognosis;    Pyruvate kinase M2 (PKM2);   

DOI  :  10.7717/peerj.8625

学科分类：社会科学、人文和艺术（综合）

来源: Inra

【 摘 要 】

Background Pyruvate kinase M2 (PKM2) is critical regulator contributing to Warburg effect. However, the expression pattern and prognostic value of PKM2 remain unknown in lung adenocarcinoma (LUAD). The aim of this study is to clarify the prognostic value of PKM2 via intergrated bioinformatics analysis. Methods Firstly, mRNA expression levels of PKM2 in LUAD were systematically analyzed using the ONCOMINE and TCGA databases. Then, the association between PKM2 expression and clinical parameters was investigated by UALCAN. The Kaplan–Meier Plotter was used to assess the prognostic significance of PKM2. Finally, the relationship between PKM2 expression and its genetic and epigenetic changes was evaluated with MEXPRESS and MethHC database. Results Pooled analysis showed that PKM2 is frequently upregulated expression in LUAD. Subsequently, PKM2 expression was identified to be positively associated with tumor stage and lymph node metastasis and also strongly correlated with worse OS (P = 2.80e−14), PPS (P = 0.022), FP (P = 1.30e−6) and RFS (P = 3.41e−8). Importantly, our results demonstrated that over-expressed PKM2 is associated with PKM2 hypomethylation and copy number variations (CNVs). Conclusion This study confirms that over-expressed PKM2 in LUAD is associated with poor prognosis, suggesting that PKM2 might act as a promising prognostic biomarker and novel therapeutic target for LUAD.

【 授权许可】

CC BY